Dr Dholaria on the Use of Liso-Cel in Relapsed/Refractory CLL


In Partnership With:

Bhagirathbhai Dholaria, MBBS, discusses the benefits and limitations of liso-cel for patients with relapsed/refractory chronic lymphocytic leukemia.

Bhagirathbhai Dholaria, MBBS, associate professor, medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, discusses the benefits and limitations of lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

In the phase 1/2 TRANSCEND CLL 004 trial (NCT03331198), patients with relapsed/refractory CLL received cyclophosphamide and fludarabine–based lymphodepletion followed by a single infusion of liso-cel. Patients in this trial were heavily pretreated; all patients had received prior BTK inhibitors, and several patients with a BTK domain mutation had prior exposure to venetoclax (Venclexta), Dholaria says.

Among patients who achieved a complete response with liso-cel, the median progression-free survival (PFS) was not yet reached at a median follow-up of approximately 24 months. The median PFS was approximately 26.9 months among patients who achieved a partial response. The median PFS was approximately 18.0 months in the overall population. The PFS outcomes were similar between patients who had received prior BCL-2 and BTK inhibitors and the overall trial population, Dholaria explains. 

Liso-cel is effective in patients with relapsed/refractory CLL, and may address some traditional factors associated with high-risk disease, including prior exposure to BTK inhibitors or BCL-2 inhibitors, Dholaria notes. However, one drawback to CAR T-cell therapy is the short-term and long-term toxicity profile associated with this agent, Dholaria emphasizes. Since lymphodepletion is necessary for in vivo CAR T cell expansion, CAR T-cell therapy may not be optimal for patients who are older and/or have several comorbidities, according to Dholaria. Furthermore, the risk of developing cytokine release syndrome and neurotoxicity is high during the first few weeks after liso-cel infusion, Dholaria says. Patients may also experience disease relapse after receiving liso-cel, indicating that this agent is not a curative therapy, Dholaria explains. Relapse-prevention strategies need to be further developed for patients who experience initial responses with liso-cel, Dholaria emphasizes.

Another limitation of CAR T-cell therapy is its cost and lack of accessibility, Dholaria notes. CAR T-cell therapy administration is limited to large academic cancer centers, which may prevent patients from receiving this treatment, Dholaria concludes.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD